HMG CoA reductase inhibitors, NSAIDs and risk of glioma

International Journal of Cancer

Volumn 131, Issue 6, 2012, Pages

  Ferris, Jennifer S ^a   McCoy, Lucie ^b   Neugut, Alfred I ^a,c   Wrensch, Margaret ^b   Lai, Rose ^a,d  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d NEUROLOGICAL INSTITUTE   (United States)

Author keywords

glioblastoma; glioma; HMG CoA reductase inhibitors; nonsteriodal anti inflammatory drugs; pharmacoepidemiology; statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; MEVINOLIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED STATES;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; GLIOMA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RAS PROTEINS; RISK;

EID: 84864133228     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27536     Document Type: Article

References (24)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
2. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS,. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-oncol 2002; 4: 278-99.
3. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM,. Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930-42.
4. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM,. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 2011; 71: 1763-71.
5. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, Gaziano JM,. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008; 100: 134-9.
6. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G,. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-92.
7. Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE,. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006; 98: 69-72.
8. Coogan PF, Smith J, Rosenberg L,. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007; 99: 32-40.
9. Ulrich CM, Bigler J, Potter JD,. Non-steriodal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-40.
10. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW,. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials. Lancet 2010; 376: 1741-50.
11. Scheurer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, Weinberg JS, Bondy ML,. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 1277-81.
12. Sivak-Sears NR, Schwartzbaum JA, Miike R, Moghadassi M, Wrensch M,. Case-control study of use of nonsteriodal anti-inflammatory drugs and glioblastoma multiforme. Am J Epidemiol 2004; 159: 1131-9.
13. Waksberg J,. Sampling methods for random digit dialing. J Am Stat Assoc 1978; 73: 40-6.
14. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI,. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004; 291: 2433-40.
15. Vuletic S, Riekse RG, Marcovina SM, Peskind ER, Hazzard WR, Alberts JJ,. Statins of different brain penetrability differentially affect CSF PLTP activity. Dement Geriatr Cogn Disord 2006; 22: 392-8.
16. Botti RE, Triscari J, Pan HY, Zayat J,. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 1991; 14: 256-61.
17. Saheki A, Terasaki T, Tamai I, Tsuji A,. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 1994; 11: 305-11.
18. Holland EC,. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001; 2: 120-9.
19. Olson MF, Paterson HF, Marshall CJ,. Signals from Ras and Rho GTPases interact to regulate expression of p21 Waf1/Cip1. Nature 1998; 394: 295-9.
20. h2 development. Circ Res 2003; 93: 948-56.
21. Linos E, Raine T, Alonso A, Michaud D, Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst 2007; 99: 1544-50.
22. Shono T, Tfilon PJ, Bruner JM, Owolabi O, Lang FF,. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001; 61: 4375-81.
23. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E,. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819-25.
24. Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL,. Epidemiology of brain tumors. Neurol Clin 2007; 25: 867-90, vii.